trending Market Intelligence /marketintelligence/en/news-insights/trending/XjV66pFS4p4Curd9BwS5lg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gene therapy biotechs ripe for M&A; Pharming eyes new use for magic rabbits drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gene therapy biotechs ripe for M&A; Pharming eyes new use for magic rabbits drug

Here are the editors' top picks for the week ended March 15.

Amid gene therapy M&A flurry, analysts zero in on biotechs ripe for takeovers

As Biogen Inc. inks the second gene therapy acquisition of 2019 with Nightstar Therapeutics PLC, analysts have highlighted four companies that might be next for pharma companies scrambling to get a foot in the regenerative medicine door.

Pharming's magic rabbits drive Ruconest beyond rare disease, pique M&A interest

Pharming Group NV, a Dutch biotech company that uses the milk of so-called "magic rabbits" to make its lead product Ruconest, intends to broaden the medicine's use beyond a rare genetic disease to address a market worth some $5.6 billion.

After 2018 gains, top pharma companies issue cautious outlook for 2019

After reporting generally profitable earnings for 2018, the pharmaceutical sector is preparing for more conservative helpings to come, judging by weaker forecasts brought on by drug pricing pressure and crowded markets.

Demand for 1st cannabis-based drug meets distribution, insurance hurdles

Prescriptions for GW Pharmaceuticals PLC's Epidiolex, the first U.S.-approved drug derived from cannabis, took as long as six weeks for pharmacies to fill, due to complex distribution and payer coverage issues surrounding the epilepsy treatment.

Capitol Checkup: HHS diverts HIV, vaccine funds ahead of FY'20 budget request

Just as the Trump administration was preparing to unveil its plan to end HIV/AIDS in the U.S. as part of its fiscal 2020 budget, its top health official told Congress he was shifting millions of dollars away from efforts to fight the disease.

BIO Asia: Ascletis aims to test PD-L1 drug for hepatitis B treatment by year-end

The company will approach Chinese regulators around the third quarter to discuss the potential to start a phase 2 study, Ascletis Pharma Inc. CFO Lindi Chan told S&P Global Market Intelligence on the sidelines of the BIO Asia conference in Tokyo.

China to start negotiations on drug reimbursement; PD-1 drugs likely to be in

Regulators said they will prioritize reimbursement for cancer, chronic disease and rare disease drugs.

Top GOP health appropriator: Congress will reject White House cuts to NIH, CDC

If there was any question about whether Republicans on Capitol Hill would back the Trump administration's plan to cut about $5 billion from the National Institutes of Health, Rep. Tom Cole, R-Okla., set the record straight: The White House is on its own.

FDA warns providers of surgical staplers' safety risks, may reclassify devices

The U.S. Food and Drug Administration told healthcare providers of the safety risks associated with surgical staplers and staples and said malfunctions in the devices have led to serious injuries and even deaths.

Azar defends ACA lawsuit, Trump's proposed health cuts, Medicaid work mandate

Health and Human Services Secretary Alex Azar defended the administration's proposal to cut billions of dollars in funding for US biomedical research and the nation's healthcare programs for seniors and low-income Americans.